Bull, J. J., Nuismer, S. L., Remien, C. H., Griffiths, M. E. and Antia, R. (2024) Recombinant transmissible vaccines will be intrinsically contained despite the ability to superinfect. Expert Review of Vaccines, 23(1), pp. 294-302. (doi: 10.1080/14760584.2024.2320845) (PMID:38372241)
![[img]](https://eprints.gla.ac.uk/style/images/fileicons/text.png) |
Text
321286.pdf - Published Version Available under License Creative Commons Attribution. 952kB |
Abstract
Introduction: Transmissible vaccines offer a novel approach to suppressing viruses in wildlife populations, with possible applications against viruses that infect humans as zoonoses – Lassa, Ebola, rabies. To ensure safety, current designs propose a recombinant vector platform in which the vector is isolated from the target wildlife population. Because using an endemic vector creates the potential for preexisting immunity to block vaccine transmission, these designs focus on vector viruses capable of superinfection, spreading throughout the host population following vaccination of few individuals. Areas covered: We present original theoretical arguments that, regardless of its R0 value, a recombinant vaccine using a superinfecting vector is not expected to expand its active infection coverage when released into a wildlife population that already carries the vector. However, if superinfection occurs at a high rate such that individuals are repeatedly infected throughout their lives, the immunity footprint in the population can be high despite a low incidence of active vaccine infections. Yet we provide reasons that the above expectation is optimistic. Expert Opinion: High vaccine coverage will typically require repeated releases or release into a population lacking the vector, but careful attention to vector choice and vaccine engineering should also help improve transmissible vaccine utility.
| Item Type: | Articles |
|---|---|
| Additional Information: | M Griffiths is supported by Wellcome Trust grant 217221/Z/19/Z to DG Streicker, SL Nuismer by grants NIH 2R01GM122079-05A1 and NSF DEB 2314616. R Antia was supported by the National Institutes of Health grants U01 AI150747 and U01 AI144616. |
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Griffiths, Dr Megan |
| Authors: | Bull, J. J., Nuismer, S. L., Remien, C. H., Griffiths, M. E., and Antia, R. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Biodiversity, One Health & Veterinary Medicine |
| Journal Name: | Expert Review of Vaccines |
| Publisher: | Taylor and Francis |
| ISSN: | 1476-0584 |
| ISSN (Online): | 1744-8395 |
| Published Online: | 28 February 2024 |
| Copyright Holders: | Copyright © 2024 The Author(s) |
| First Published: | First published in Expert Review of Vaccines 23(1):294-302 |
| Publisher Policy: | Reproduced under a Creative Commons licence |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information